- PATIENT PLANS
- ABOUT US
- CONTACT US
Caregivers, cancer patients, and loved ones, you can watch this webinar about childhood cancer by Dr. Jason Freedman, Dr. Gerald Wertheim and Dr. Sarah Tasian.
If you missed the webinar, you can still watch the recording here.
Caregivers, patients, and loved ones joined Dr. Belisario Arango and Dr. Arturo Loaiza-Bonilla on Monday, June 19, 12 pm EDT for this very informative and interactive question and answer panel format webinar.
Our doctors answered participants questions submitted during the webinar and ones that have been sent to Massive Bio.
Bringing state-of-the-art precision cancer care was aired Tuesday, March 14 at 12:00 EDT.
Dr. Belisario Arango covered the following topics:
Why there is a higher cancer prevalence in patients in rural areas?
What are the challenges delivering cancer care to patients?
Where is the future of cancer care going?
Massive Bio is in the holiday spirit this year, so we are starting our Black Friday deal early and ending it late! Give thanks to those you love by giving them the gift of Massive Bio to find the best cancer treatment for your loved one or for yourself.
Precision oncology encompasses the implementation of high level of evidence disease-specific and biomarker-driven diagnostic and treatment recommendations for optimized cancer care.
September 19, 2017
Much has been said and written about the lack of women in the tech sector, be it as investors (or associates), founders, or in management positions at major companies. Is the problem the old boys network – or that success in technology is seen as a young man’s game? In this series, we speak with some of the top women in tech in New York as they discuss the challenges they face, the perceptions that need to be changed and the work that’s being done – or not – to help to promote women in tech.
Today we speak with Dr. Selin Kurnaz, CEO and cofounder of Massive Bio. After emigrating from Turkey and completing a PhD at the University of Michigan, receiving multiple engineering degrees, Selin spent more than a specializing in delivering revenue enhancement, margin optimization and capital efficiency improvements for Pharmaceutical and Life Science companies. Her startup, Massive Bio, brings the latest knowledge in cancer care to patients treated at community practices in the US and worldwide. Selin has written and spoke extensively about life sciences in tech and how to deliver information in creative ways.
Into Global Business Communications Co., Ltd. (INTO) organized the first AI & big data health tech program successfully in New York this April.
Cancer specialists and researchers from the American Society of Clinical Oncology (ASCO), released a statement this week, that drinking alcohol is linked with cancer. Their statement was published titled, “Alcohol and Cancer: A Statement of the American Society of Clinical Oncology”, in the Journal of Clinical Oncology.
Generally, prostate cancer patients who have failed standard radiation therapy have the options of surgery, radioactive seed implantation or cryoablation. These treatments are invasive and can have serious side effects.
The HudsonAlpha Institute for Biotechnology is continuing a program which gives thousands the opportunity to know what cancer risks they may have based on their genetics at no cost as a part of its Information is Power initiative.
New research on the origin of ovarian cancer may open the door to early detection of the disease, which could lead to the development of life-saving therapies, the chief science officer of the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation said Friday.
Docetaxel-based chemotherapy led to significant improvement in progression-free (PFS) and overall survival for patients with resectable gastric or gastroesophageal juncture (GEJ) cancer, according to a study reported at the European Society for Medical Oncology conference in Madrid.
Liposuction for primary or secondary lymphedema led to substantial reductions in limb swelling and associated pain, according to a case report in the New England Journal of Medicine.
A PARP inhibitor demonstrated activity in triple-negative breast cancer (TNBC) xenografts without BRCA1/2 mutations, investigators reported online in Clinical Cancer Research.
The types and diversity of gut bacteria had a significant association with response to anti-PD-1 immunotherapy, according to two studies published in Science.
Cancer patients, caregivers and oncologists - we would like to introduce ourselves as your next step toward fighting cancer. Massive Bio, Inc., headquartered in New York, is an innovative digital health company that brings the latest and greatest in cancer care to the point of need.